Home Earnings Analysis Healthcare  Summary AstraZeneca delivered robust Q1 2026 results, with revenues up 8% year-on-year and operating profit rising 17%. AZN's oncology division remains a powerhouse, driving ~45% of revenues, with six blockbuster drugs and a deep pipeline supporting long-term growth. Despite Farxiga's looming US patent expiry, rare disease and oncology divisions are expected to offset declines, targeting overall $80bn annual revenues by 2030. I view AZN as a solid long-term buy-and-hold, anticipating at least 30% share price appreciation by 2030, though near-term upside appears limited. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » babyrhino/iStock via Getty Images Investment Overview AstraZeneca ( AZN ), the United Kingdom-headquartered Pharma giant, announced its Q1 2026 earnings today.…